Everything below concerns lyophilization. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
=== EC 1.10.3 With oxygen as acceptor === EC 1.10.3.1: catechol oxidase EC 1.10.3.2: laccase EC 1.10.3.3: L-ascorbate oxidase EC 1.10.3.4: o-aminophenol oxidase EC 1.10.3.5: 3-hydroxyanthranilate oxidase EC 1.10.3.6: rifamycin-B oxidase EC 1.10.3.7: Now EC 1.21.3.4, sulochrin oxidase [(+)-bisdechlorogeodin-forming] EC 1.10.3.8: Now EC 1.21.3.5, sulochrin oxidase [(-)-bisdechlorogeodin-forming] EC 1.10.3.9: photosystem II EC 1.10.3.10: Now EC 7.1.1.3, ubiquinol oxidase (H+-transporting) EC 1.10.3.11: ubiquinol oxidase (non-electrogenic) EC 1.10.3.12: Now EC 7.1.1.5, menaquinol oxidase (H+-transporting) EC 1.10.3.13: Now EC 7.1.1.4, caldariellaquinol oxidase (H+-transporting) EC 1.10.3.14: Now EC 7.1.1.7, ubiquinol oxidase (electrogenic, proton-motive force generating) EC 1.10.3.15: grixazone synthase EC 1.10.3.16: dihydrophenazinedicarboxylate synthase EC 1.10.3.17: superoxide oxidase
== Treatment == Benign fibromas may, but need not, be removed. Removal is usually a brief outpatient procedure or using cryotherapy in which the lesion is deep frozen (-196 degrees Celsius using liquid nitrogen) and thawed for two or more cycles, with full recovery within 3 to 4 weeks. The cryotherapy treatment needs no anesthetics and is painless. Another simple treatment is snip removal after injecting local anesthetic.
== Career == Daly worked as a physical science instructor at Howard University, from 1947 to 1948 while simultaneously conducting research under the direction of Herman Branson. After being awarded an American Cancer Society grant to support her postdoctoral research, she joined Alfred E. Mirsky's group at the Rockefeller Institute, which studied the cell nucleus and its constituents. This was the start of a seven-year research program at the Rockefeller Institute of Medicine, where Daly examined how proteins are constructed in the body. At the time, the structure and function of DNA were not yet understood. Daly began working in the College of Physicians and Surgeons at Columbia University in 1955. In collaboration with Quentin B. Deming, she studied arterial metabolism. She continued this work as an assistant professor of biochemistry and of medicine at the Albert Einstein College of Medicine at Yeshiva University, where she and Deming moved in 1960. From 1958 to 1963, she also served as an investigator for the American Heart Association. During her final years at Albert Einstein College, per Daly's efforts to increase minority enrollment in professional and graduate schools, she helped run the Martin Luther King -Robert F. Kennedy program to help prepare black students for admission. In 1971 she was promoted to associate professor. In 1975, Daly was one of 30 minority women scientists to attend a conference examining the challenges facing minority women in STEM fields. The conference was held by the American Association for the Advancement of Science.
As a mere graduate student, in 1972 Candace Pert discovered the brain’s opiate receptor – the cellular site where the body’s painkillers and "bliss-makers", the endorphins – bond with cells to weave their magic. Pert's discovery led to a revolution in neuroscience, helping open the door to the "information-based" model of the brain which is now replacing the old "structuralist" model... Molecules of Emotion begins as an eye-opener into the intellectual warfare of modern scientific discovery – the gamesmanship, the sly purloining of others' results – but also into the round-the-clock work, the exhilaration of a shared breakthrough, and the slow, painful rise of women in the scientific professions. The book concludes with the author integrating the science she pioneered with the holistic "energy medicines" which work on the same principles – till now without scientific rationales.
== Pregnancy == Scleroderma in pregnancy is a complex situation; it increases the risk to both mother and child. Overall, scleroderma is associated with reduced fetal weight for gestational age. The treatment for scleroderma often includes known teratogens such as cyclophosphamide, methotrexate, mycophenolate, etc., so careful avoidance of such drugs during pregnancy is advised. In these cases hydroxychloroquine and low-dose corticosteroids might be used for disease control.
Sources: en.wikipedia.org
: equilibrium In order to meet the thermodynamic condition for equilibrium, the Gibbs energy must be stationary, meaning that the derivative of G with respect to the extent of reaction, ξ, must be zero. It can be shown that in this case, the sum of chemical potentials times the stoichiometric coefficients of the products is equal to the sum of those corresponding to the reactants. Therefore, the sum of the Gibbs energies of the reactants must be the equal to the sum of the Gibbs energies of the products.
25 April Elements of the PAVN 271st Regiment attacked Patrol Base Frontier City southeast of Tây Ninh. The attack was countered with intensive fire from fixed wing and helicopter gunships and the PAVN lost 214 killed and six captured for no U.S. losses.
Samples are transported daily to the laboratory responsible for testing. In the United States and Canada, newborn screening is mandatory, with an option for parents to opt out of the screening in writing if they desire. In many regions, NBS is mandatory, with an option for parents to opt out in writing if they choose not to have their infant screened. In most of Europe, newborn screening is done with the consent of the parents. Proponents of mandatory screening claim that the test is for the benefit of the child, and that parents should not be able to opt out on their behalf. In regions that favour informed consent for the procedure, they report no increase in costs, no decrease in the number of children screened and no cases of included diseases in children who did not undergo screening.
== Cast == Keanu Reeves as Eddie Kasalivich, a machinist working on a team from the University of Chicago; he is forced to go on the run with Dr. Lily Sinclair when someone frames him for the murder of his boss, Dr. Alistair Barkley, and the destruction of his laboratory, and both must work to clear their names before they are captured or killed Morgan Freeman as Paul Shannon, the enigmatic leader of the project at the University of Chicago; his motives are unclear throughout the movie, but he advises Eddie to turn himself into the authorities. It is later disclosed that he is the head of the entire program that includes Lyman, who tries to kill the research team. A scene with Agents Ford and Doyle and the ending suggests Shannon is with the CIA. Rachel Weisz as Dr. Lily Sinclair, a physicist working with Dr.
Unlike aerated chocolates produced with large bubbles, micro-aerated chocolate has nitrogen beaten into the mixture. The resulting chocolate, different not only in bubble size but also flavour and texture. This is theorised to arise from the gas having a different solubility. Aerated chocolates containing long tubes of air are also created using this technique, but their distinction comes from how the aerated chocolate is extruded rather than set in a moulded shell. The final type, those held together by a skeleton of solid particles, are produced using water evaporation methods. In the first of these, sugar is dissolved in water. This solution is emulsified with cocoa liquor and milk solids, which is evaporated and then dried using industrial machinery, until the product contains less than 2% water. In the second, water is emulsified with liquid chocolate and set and then freeze dried, removing the water.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.